We will use our extensive expertise in bioinformatics, machine learning, artificial intelligence and data mining to co-develop a unique proprietary clinical diagnostic algorithm for Novigenix LITOseek platform. The LITOseek platform makes use of disease specific gene expression modifications (mRNA signatures) found in blood samples combined with artificial intelligence based algorithms to predict onset and progression of colon cancer. We will co-develop disease specific algorithms integrating mRNA signatures with additional clinical and medical data. Combining mathematical models and machine learning tools we can enable continuous adaptation and improvement of these learning algorithms.

“We’re proud to collaborate with Novigenix which is developing innovative tests for early cancer detection and therapy monitoring,”

– Dr. Gerben Menschaert

“Partnering with BioLizard helps us to fast track the development of our LITOseek platform,” said Dr. Jan Groen, CEO of Novigenix in a recent interview. “Our current Colox customers will strongly benefit from this new development once we launch our new colon cancer test on the LITOseek platform, but it will also fast track the progress of new products that are currently in the pipeline.”

Read more about the press release here.